CN113995821B - Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof - Google Patents

Abstract

The invention discloses a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method thereof, wherein the traditional Chinese medicine composition comprises the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice. The traditional Chinese medicine composition or the traditional Chinese medicine preparation contains various active ingredients such as honeysuckle, white mulberry root-bark, mix-fried ephedra herb and the like, the white mulberry root-bark is used for freeing lung and releasing heat, and the honeysuckle is used for clearing heat and detoxicating and relieving exterior syndrome and expelling evil, and is a monarch drug; the ephedra stem is used for diffusing lung and relieving asthma, the almond is used for descending the lung and qi, and the lung qi is used as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and fragrant and dries dampness, rhizoma atractylodis macrocephalae strengthens spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening spleen, and the Chinese medicinal preparation has obvious treatment effect on various viral pneumonia including novel coronavirus pneumonia.

Description

Traditional Chinese medicine composition and preparation for treating novel coronavirus and pneumonia of other viruses and preparation method

Technical Field

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method.

Background

Viral pneumonia is an inflammation of the lungs caused by viral infection of the upper respiratory tract, spreading downward. The disease can occur all the year round, but it is common in winter and spring, and it can be fulminating or spreading epidemic. The clinical manifestations are fever, headache, general aching pain, dry cough and lung infiltration. Viral pneumonia occurs in association with the virulence of the virus, the route of infection, as well as the age and immune function status of the host.

At present, the antiviral drugs such as neuraminidase inhibitor and the like are used in the early stage of infection of influenza virus and avian influenza virus, so that the virus can be cleared in time, and pneumonia can be prevented or delayed. The viral pneumonia lacks effective medicine, and western medicine clinical treatment is mainly carried out according to symptoms. Including pneumonia caused by the novel coronavirus which is epidemic in 2020, and specific medicines are also lacking clinically. The traditional Chinese medicine has different technical characteristics for treating viral pneumonia. The traditional Chinese medicine formulates a treatment rule on the basis of determining the core pathogenesis, and has important clinical value for preventing and treating the viral pneumonia by screening effective traditional Chinese medicine combinations for treating the viral pneumonia. Therefore, how to obtain a traditional Chinese medicine composition, a preparation and a preparation method which can effectively treat the novel coronavirus and other viral pneumonia by compounding is a technical problem to be solved at present.

Disclosure of Invention

Therefore, the invention provides a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, a preparation and a preparation method thereof, and aims to solve the problem that the traditional Chinese medicine preparation has poor effect on treating the novel coronavirus and other virus pneumonia.

In order to achieve the above purpose, the invention provides the following technical scheme:

according to the first aspect of the invention, the invention provides a traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia, which comprises the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.

Further, the composition comprises the following active ingredients in parts by weight: 12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

Further, the composition comprises the following active ingredients in parts by weight: 18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.

According to a second aspect of the present invention, the present invention provides a Chinese medicinal preparation, which comprises an auxiliary agent and the following active ingredients in parts by weight: 9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice; the auxiliary agent comprises one or more of filler, adhesive, disintegrant, lubricant, surfactant and flavoring agent.

Further, the filler includes one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.

Further, the binder comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone.

Further, the traditional Chinese medicine preparation comprises the following active ingredients in parts by weight: 12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra, 6-15 parts of fried bitter apricot kernels, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

Further, the traditional Chinese medicine preparation comprises the following active ingredients in parts by weight: 18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.

According to a third aspect of the present invention, the present invention provides a method for preparing the above-mentioned Chinese medicinal preparation, comprising the steps of:

s1, putting a plurality of active ingredients into water, heating and decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;

s2, adding a plurality of auxiliary agents into the traditional Chinese medicine liquid, stirring, and making and forming.

The invention has the following advantages:

the traditional Chinese medicine composition or the traditional Chinese medicine preparation contains various active ingredients such as honeysuckle, white mulberry root-bark, mix-fried ephedra herb and the like, the white mulberry root-bark is used for freeing lung and releasing heat, and the honeysuckle is used for clearing heat and detoxicating and relieving exterior syndrome and expelling evil, and is a monarch drug; the ephedra stem can ventilate lung and relieve asthma, the almond can descend lung and descend qi, and the lung qi is opened as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and dampness-drying, rhizoma atractylodis macrocephalae invigorates the spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening the spleen; the radix scrophulariae has the effects of clearing heat and cooling blood, nourishing yin and clearing heat, the lithospermum has the effects of cooling blood and activating blood, and detoxifying and expelling pathogenic factors, and the radix lithospermi and the lithospermum have the effects of assisting the honeysuckle, moistening the clear water, eliminating pathogenic factors and not damaging yin, and are also ministerial drugs; the radix curcumae promotes qi and activates blood circulation, the magnolia officinalis lowers qi and purges the hollow viscera, the magnolia flower dispels wind and unblocks orifices, the monarch and minister drugs are assisted by the radix curcumae, the magnolia officinalis lowers qi and purges bowels, the raw licorice root and the other drugs play a role in treatment, and the radix curcumae, the magnolia officinalis, the magnolia flower and the other drugs have obvious treatment effects on various viral pneumonia including novel coronavirus pneumonia.

Detailed Description

The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

The embodiment provides a traditional Chinese medicine composition for treating novel coronavirus and other viral pneumonia, which comprises the following active ingredients in parts by weight:

9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.

Through repeated epidemic situation practices, the Chinese medicine core pathogenesis of the viral pneumonia is gradually realized as epidemic toxin attacking lung, lung qi obstruction, qi activity disorder, spleen failure in transportation and blood stasis in collaterals. Treating viral pneumonia by dispersing lung qi, removing toxic substance, invigorating spleen, regulating qi-flowing, inducing resuscitation and removing blood stasis. Through repeated clinical practice and screening, a hospital-agreed prescription for treating viral pneumonia, namely a jintong detoxification prescription, is gradually formed, namely the traditional Chinese medicine composition formula of the embodiment.

In the traditional Chinese medicine composition of the embodiment, the white mulberry root-bark is used for freeing lung and clearing heat, and the honeysuckle is used for clearing away heat and toxic materials and relieving exterior syndrome and expelling pathogenic factors and is a monarch drug; the ephedra stem is used for diffusing lung and relieving asthma, the almond is used for descending the lung and qi, and the lung qi is used as a ministerial drug for regulating qi; rhizoma atractylodis is spicy and dampness-drying, rhizoma atractylodis macrocephalae invigorates the spleen and eliminates dampness, and the common effects of strengthening the middle energizer are ministerial drugs for strengthening the spleen; the radix scrophulariae has the effects of clearing heat, cooling blood, nourishing yin and clearing heat, the lithospermum has the effects of cooling blood, activating blood, detoxifying and expelling pathogenic factors, and the radix scrophulariae and the lithospermum assist the honeysuckle to moisten the serum and eliminate pathogenic factors without damaging yin, so that the radix scrophulariae is also a ministerial drug; the radix curcumae has the effects of promoting qi and activating blood, the magnolia officinalis has the effects of depressing qi and clearing hollow viscera, the magnolia officinalis has the effects of dispelling wind and dredging orifices, the monarch and ministerial drugs are assisted by the radix curcumae, the magnolia officinalis has the effects of dispelling wind and dredging orifices, and the raw liquorice has the effect of regulating the functions of the other drugs in the prescription.

Moreover, multiple clinical applications prove that the traditional Chinese medicine composition has a remarkable treatment effect on various viral pneumonia including novel coronavirus pneumonia.

Example 2

The traditional Chinese medicine composition described in example 1 comprises the following active ingredients in parts by weight:

12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra, 6-15 parts of fried bitter apricot kernels, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

In the traditional Chinese medicine composition, the ratio of the active ingredients is better than that of the composition in the embodiment 1, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition, the effect is more rapid, and the patients can recover to a healthy state in a shorter time.

Example 3

The traditional Chinese medicine composition described in embodiment 2 comprises the following active ingredients in parts by weight:

18 parts of honeysuckle, 15 parts of white mulberry root-bark, 6 parts of mix-fried ephedra herb, 9 parts of stir-fried bitter apricot seed, 9 parts of officinal magnolia bark, 15 parts of figwort root, 9 parts of turmeric root-tuber, 15 parts of swordlike atractylodes rhizome, 9 parts of biond magnolia flower, 15 parts of largehead atractylodes rhizome, 15 parts of sinkiang arnebia root and 6 parts of raw liquoric root.

The ratio of the active ingredients in the traditional Chinese medicine composition in the embodiment is better than that in the embodiment 2, compared with the traditional Chinese medicine composition in the embodiment 2, after the traditional Chinese medicine composition in the embodiment is taken by various patients with viral pneumonia including novel coronavirus pneumonia, the effect is more quickly achieved, the patients can recover to a healthy state in a shorter time, and the traditional Chinese medicine composition in the embodiment has a more obvious treatment effect on some patients with severe viral pneumonia.

The traditional Chinese medicine composition in the above embodiments 1-3 can be decocted with water for administration, twice a day, one dose a day, convenient and fast.

Example 4

The embodiment provides a traditional Chinese medicine preparation, which comprises an auxiliary agent and the following active ingredients in parts by weight:

9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice;

the auxiliary agent comprises one or more of filler, adhesive, disintegrant, lubricant, surfactant and flavoring agent.

The traditional Chinese medicine preparation contains the extracts of the active ingredients and various auxiliaries, is a traditional Chinese medicine preparation which is prepared from traditional Chinese medicines and auxiliaries and can be directly taken, can be in various forms such as decoction, pills and tablets, is convenient to carry and take, does not need manual decoction, can be conveniently purchased from a hospital or a pharmacy and then taken, and has better portability.

Example 5

The herbal formulation of embodiment 4, wherein the filler comprises one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.

The fillers listed in the embodiment can increase the weight or volume of the tablet, facilitate the forming and cause no adverse reaction to human bodies.

Example 6

The herbal formulation of embodiment 5, wherein the binder comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone. Several binders mentioned in this example facilitate the binding of the various components into tablets with good binding stability.

Example 7

The traditional Chinese medicine preparation of embodiment 6, which comprises the following active ingredients in parts by weight:

12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

In the traditional Chinese medicine preparation of the embodiment, the ratio of the active ingredients is better than that in the embodiment 4, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition of the embodiment, the effect is more rapid, and the patients can recover to a healthy state in a shorter time.

Example 8

The traditional Chinese medicine preparation of embodiment 7, which comprises the following active ingredients in parts by weight:

18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.

In the traditional Chinese medicine preparation of the embodiment, the ratio of the active ingredients is better than that in the embodiment 7, after a plurality of patients with viral pneumonia including novel coronavirus pneumonia take the traditional Chinese medicine composition of the embodiment, the effect is quicker, the patients can recover to a healthy state in a shorter time, and the traditional Chinese medicine composition of the embodiment has a more obvious treatment effect on some patients with severe viral pneumonia.

Example 9

This example provides a method of preparing the chinese herbal preparation of any of examples 4-8, comprising the steps of:

s1, putting a plurality of active ingredients into water, heating, decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;

s2, adding a plurality of auxiliary agents into the traditional Chinese medicine liquid, stirring, and making and forming.

The method for preparing the traditional Chinese medicine preparation in the embodiment can also comprise a drying step after the preparation and the forming, and the preparation of the traditional Chinese medicine preparation in the forms of tablets, pills and the like can be obtained through stirring, preparation and forming and drying. The Chinese medicinal liquid obtained by heating, decocting, standing, filtering and concentrating in the step S1 can be directly taken as decoction.

The method for preparing the traditional Chinese medicine preparation is simple, low in cost and easy for industrial mass production.

Test example 1

1. The study included 96 patients, 48 of whom were treated with the herbal formulation of example 8, and 48 of whom were in the placebo group.

2. And (3) inclusion standard:

(1) The pneumonia diagnosis standard person accords with 'community-acquired pneumonia diagnosis and treatment guide' of respiratory disease society of Zhonghua medical society in 2015; (2) clinical diagnosis of viral pneumonia is met: (1) fever with respiratory symptoms with or without dyspnea (respiratory rate >30 beats/min); (2) normal or low white blood cells with or without thrombocytopenia; (3) breast imaging (breast CT): unilateral or bilateral chest imaging manifested as multiple (at least 2 lesions) or diffusely distributed mottled or frosty glass infiltration shadows (with or without solid ghost); (3) the disease is developed within 5 days; (4) the age is 14-75 years, with no limitation; (5) Written informed consent was approved before the study began (non-behavioral subjects, if the investigator deemed the subjects eligible for their own benefit to participate in the trial, were to be signed with their legal guardian and described in the original medical record or other relevant documentation).

3. Exclusion criteria:

(1) There is clear evidence of bacterial infection, PCT >1ug/L; (2) Treating with other antiviral drugs including antiviral indication Chinese medicinal materials within 1 week before screening; (3) Those who meet the diagnosis standard of severe pneumonia in 2015 "guidelines for diagnosis and treatment of community-acquired pneumonia"; (4) Chest CT confirms that patients with serious lung interstitial diseases, bronchiectasis and other basic lung diseases exist; (5) Patients who are positive for streptococcus pneumoniae and legionella pneumophila urine antigens, mycoplasma pneumoniae, chlamydia antibodies; (6) severe liver and kidney dysfunction: (1) ALT and AST exceed the upper limit of normal value by more than 3 times. (2) Serum creatinine 1.5 times higher than the upper limit of the normal value; psychotic patients; (7) The disease, whether it has or is now, may affect the patient's participation in the study or affect the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney diseases, hematopathy, nervous system diseases, and endocrine diseases; (8) diseases that severely affect the immune system are present, such as: human Immunodeficiency Virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; (9) A history of seizures, or psychiatric conditions that may affect regimen compliance, or a history of abuse of alcohol or illicit drugs; (10) pregnant or lactating women; (11) other investigators considered unsuited to this trial.

4. Intervention protocol

(1) Sources of drugs

Name of the test drug: the jintong detoxification decoction particles comprise (1) the traditional Chinese medicine preparation described in the embodiment 8, wherein the traditional Chinese medicine preparation comprises, by weight, 18 parts of honeysuckle, 15 parts of white mulberry root-bark, 6 parts of roasted ephedra, 9 parts of fried bitter apricot kernel, 9 parts of magnolia officinalis, 15 parts of figwort, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of bighead atractylodes rhizome, 15 parts of lithospermum and 6 parts of raw liquorice, (2) the characteristics that the jintong detoxification decoction particles are brown to brown particles, and the specifications of slightly bitter taste and slight fragrance, (3) the ingredients are 6g per bag.

Placebo: jintong detoxification prescription granule simulant (the simulant is completely consistent with the test medicine in the aspects of color, specification, package, label, content shape, etc.)

(2) Treatment regimens

In addition to the study drugs, specific therapeutic drugs are referred to the "guidelines for diagnosis and treatment of community-acquired pneumonia" 2015 edition of respiratory disease of the Chinese medical society. (1) Antiviral western medicines and traditional Chinese medicines for resisting virus indications such as Xiyanping, redunning, phlegm-heat clearing, jinhuaqinggan and radix isatidis can not be used in principle within one week before the study and after the random grouping period; (2) when antibiotics, hormones, antipyretic analgesic, cough and asthma relieving medicines are used, the name, the dosage, the use times and the duration of the medicines are strictly recorded in a case report table; (3) during the research period, the name, the dosage, the use times and the duration of the medicine which needs to be taken for other diseases are recorded in a case report table; (4) receive medication for better management of hypertension, angina, diabetes or other diseases. The course of medication in this study was 7 days, and subjects were evaluated for compliance and adverse drug reactions were recorded.

5. Clinical observation endpoints and indices

(1) The main effectiveness indexes are as follows:

rate of remission of clinical symptoms.

(2) Secondary effectiveness index:

(1) the proportion of the blood oxygen saturation to return to normal; (2) the time for relieving the single symptoms of fever, cough, expectoration and the like; (3) the length of stay; (4) time to progression (shift to RICU); (5) incidence of pneumonia complications; (6) and the combined utilization rate of antibiotics.

(3) The safety index is as follows:

(1) evaluating adverse events; (2) clinical laboratory indexes: routine blood, urine and stool, and biochemical serum (CK, ALT, AST, bun, cr); (3) 12-lead electrocardiogram; (4) and (5) physical examination.

(4) Therapeutic efficacy judgment criteria

Refer to the standard of the people's republic of China, the standard of curative effect of Chinese medicine disease diagnosis, and the guidelines of clinical research on new Chinese medicines (trial implementation).

The clinical symptom scores for the remission (%) of clinical symptoms for the two groups of subjects are shown in table 1 below:

TABLE 1

/>

(5) Results of the study

The study used the total integrated remission of clinical symptoms as the primary observation. After 7 days of treatment, the clinical symptom relief rate of the treatment group is better than that of the control group, and the treatment group has statistical significance (P is less than 0.001).

The clinical symptom relief rate of 7 days of the Jintong detoxification prescription study is shown in the table 2:

table 2:

note 1: clinical symptom relief rate (%) = (pre-treatment clinical symptom score-treatment 7 day clinical symptom score)/pre-treatment score × 100%.

Note 2: statistical analysis was performed after LOCF principle of treatment for 7 days with missing clinical symptom scores.

* Wilcoxon rank sum test

6. Conclusion of the study

The results of the intervention study of the Jintong detoxification prescription on the viral pneumonia show that the clinical symptom relief rate of the test group is better than that of the control group (P < 0.05). The Jintong detoxification prescription is suggested to have better clinical curative effect on treating viral pneumonia (because the test example selects lighter patients, the patients in the control group have certain self-healing effect).

Test example 2

Viral pneumonia typical case 1: -H7N 9 avian influenza pneumonia

For a female, 41 years old, the patient was admitted to the hospital 4/14 days in 2017 because of "general malaise for 7 days, high fever and cough for 5 days". 7 days in the course of disease, weakness at the beginning of the disease, malaise all over the body, high fever for 5 days, 40 ℃, accompanied by muscle pain, headache, cough, yellow sputum cough and suffocating, CT shows of the chest of the hospital: right lung pneumonia, poor curative effect in the hospital. The medical history of pursuing questions: poultry (chickens) died of illness were contacted before illness; and was in intimate contact with the mother 2 weeks ago, and his mother died from "pneumonia" 1 week ago. Admission to the examinee: t36.7 ℃, P76 times/min, R25 times/min, BP103/67mmHg. The traditional Chinese medicine composition has the advantages of clearing mind, promoting respiration, treating acute symptoms, treating throat congestion, making percussion of both lungs into clear sound, making respiratory sound of both lower lungs weak, making moist and crackling the right lower lung, and avoiding abnormality of heart and abdomen. Testing after admission: blood gas (not inhaled oxygen) PO26.74Kpa. Blood normal WBC3.30 × 109/L, LY%20.90%, NE%74.61%. CRP80mg/L, PCT0.73ng/ml, ESR40.0mm/h. Liver function ALT215.7U/L, AST122.3U/L, ALB37.2g/L, GGT231.9U/L. Influenza a universal nucleic acid: and (4) positive. And (4) sending to market CDC: pharyngeal swab, sputum H7N9 nucleic acid positive. Chest CT: inflammation of both lungs and inflammation of both lower lobes. And (3) diagnosis: human is infected with H7N9 avian influenza virus pneumonia. The traditional Chinese medicine decoction prepared from the traditional Chinese medicine composition in the embodiment 5 is administered for dispersing lung qi, detoxifying, invigorating spleen, regulating qi, dredging orifices and dissipating blood stasis. After 1 week of treatment, the patients have better condition than before, no obvious suffocation, cough relief, occasional phlegm, blood in phlegm, appetite, 1-2 times of defecation without dryness, gradually reduced oxygenation condition, pale and swollen tongue, white and greasy fur, peeled tongue root and tongue fur, yellowish and mild pulse condition.

Test example 3

Viral pneumonia typical case 2: -influenza virus pneumonia

Some patient, male, 56 years old. Fever is not caused by obvious inducement in 1 month in 2018, the body temperature is 40 ℃ at most, the fever is accompanied by chilliness, shivering, muscular soreness of the whole body, headache, hypodynamia, nasal obstruction and running nose, cough, yellow white sticky phlegm and difficult cough, the body temperature can be reduced to normal by oral medication in community hospitals, the cough is not relieved, suffocation occurs, the weight is obviously increased after activity, the patient is diagnosed in the outpatient service of the great-rise hospital in 1 month and 13 days, and the chest CT examination prompt: the diploponic exudative inflammation considers lung infection, the influenza A antigen is checked to be positive in hospital within 1 month and 14 days, oseltamivir is used for resisting virus, cefoxitin sodium, levofloxacin and moxifloxacin are used for resisting infection, suffocation of a patient is not relieved, chest X-ray is rechecked within 1 month and 17 days, diploponic exudative lesions are obviously aggravated, a reinforcer 80mg BID is added within 1 month and 18 days, the rechecking chest imaging is improved, but the suffocation of the patient is not relieved, and the checking of blood gas prompts the type I respiratory failure. 2018-1-24 days, after 10 weeks of treatment, the patient's condition is obviously improved, no obvious breath holding, cough relieving, occasional phlegm, appetite stimulating, 1-2 days of defecation, pale tongue with yellowish fur and rapid pulse.

Test example 4

Viral pneumonia typical case 3: -novel coronavirus pneumonia

The patient is old a certain number of men, aged 57 years, and has a family in Hebei. Cough expectoration, no fever, no asthma, no abdominal pain, no diarrhea, no nausea and no vomiting appear in 2 months in 2020, the result of the nucleic acid detection of the new coronavirus from the Korean CDC throat swab is positive, 2020-2-25 is sent to a three-room fixed-point hospital, 2020-2-26 is used for routine blood-checking: WBC 3.6X 109/L, N45.1%, L1.3X 109/L, EOS 0.8X 109/L, CRP 8.0mg/L. ALT 18U/L, GLU 6.08mmol/L, BUN 4.3mmol/L, cr 76umol/L, K3.62 mmol/L, no obvious abnormality was found in blood coagulation related examination, chest CT showed: 1. the right superior pulmonary lobe bullae; 2. inflammation of the right middle lung lobe; 3. the posterior segment of the upper lobe and the lower lobe of the right lung are frequently suffered from old lesions; 4. the right pleura was slightly thickened and was confirmed to be pneumonia (common type) infected with a novel coronavirus. The traditional Chinese medicine decoction prepared from the traditional Chinese medicine composition in the embodiment 5 is administered for dispersing lung qi, detoxifying, invigorating spleen, regulating qi, dredging orifices and dissipating blood stasis. After 2 weeks of treatment. The symptoms of the patients are obviously improved without complaints. Chest CT indicates that the density of the lobe mill glass in the right lung of 2-28 is greatly absorbed, the real deformation range is slightly reduced, the new corona nucleic acid is negative twice continuously, and then the patient is discharged.

Although the invention has been described in detail with respect to the general description and the specific embodiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (9)

1. A traditional Chinese medicine composition for treating novel coronavirus and other virus pneumonia is characterized by comprising the following active ingredients in parts by weight:

9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice.

2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following active ingredients in parts by weight:

12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

3. The traditional Chinese medicine composition according to claim 2, which is characterized by comprising the following active ingredients in parts by weight:

18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.

4. The traditional Chinese medicine preparation is characterized by comprising an auxiliary agent and the following active ingredients in parts by weight:

9-36 parts of honeysuckle, 6-30 parts of cortex mori, 3-12 parts of mix-fried ephedra, 3-18 parts of fried bitter apricot kernels, 3-18 parts of mangnolia officinalis, 6-30 parts of radix scrophulariae, 3-18 parts of radix curcumae, 6-30 parts of rhizoma atractylodis, 3-18 parts of magnolia flower, 6-30 parts of bighead atractylodes rhizome, 6-30 parts of lithospermum and 3-18 parts of raw liquorice;

the auxiliary agent comprises one or more of filler, adhesive, disintegrant, lubricant, surfactant and flavoring agent.

5. The traditional Chinese medicine formulation of claim 4, wherein the filler comprises one or more of starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, and glucose.

6. The herbal formulation of claim 5, wherein the binding agent comprises one or more of a cellulose derivative, alginate, gelatin, and polyvinylpyrrolidone.

7. The traditional Chinese medicine preparation according to claim 6, wherein the traditional Chinese medicine preparation comprises the following active ingredients in parts by weight:

12-24 parts of honeysuckle, 9-18 parts of cortex mori, 3-9 parts of mix-fried ephedra herb, 6-15 parts of fried bitter apricot seed, 6-15 parts of mangnolia officinalis, 9-18 parts of radix scrophulariae, 6-15 parts of radix curcumae, 9-18 parts of rhizoma atractylodis, 6-15 parts of magnolia flower, 9-18 parts of bighead atractylodes rhizome, 9-18 parts of lithospermum and 3-12 parts of raw liquorice.

8. The traditional Chinese medicine preparation according to claim 7, wherein the weight parts of active ingredients in the traditional Chinese medicine preparation are as follows:

18 parts of honeysuckle, 15 parts of cortex mori, 6 parts of roasted ephedra herb, 9 parts of fried bitter apricot seed, 9 parts of mangnolia officinalis, 15 parts of radix scrophulariae, 9 parts of radix curcumae, 15 parts of rhizoma atractylodis, 9 parts of magnolia flower, 15 parts of rhizoma atractylodis macrocephalae, 15 parts of lithospermum and 6 parts of raw liquorice.

9. A method of preparing the Chinese medicinal formulation of any one of claims 4 to 8, comprising the steps of:

s1, putting a plurality of active ingredients into water, heating and decocting, standing, filtering and concentrating to obtain a traditional Chinese medicine liquid;

and S2, adding a plurality of auxiliaries into the traditional Chinese medicine liquid, stirring, and making and forming.